Pulmonary Arterial Hypertension
Adults with PAH lose around 8% of annual workdays due to inpatient, outpatient care
SAN DIEGO — During 2019 and 2020, patients with pulmonary arterial hypertension lost around 8% of available workdays, according to research presented at the American Thoracic Society International Conference.
ESC scoring tool predicts survival in SSc-associated pulmonary arterial hypertension
The 2022 European Society of Cardiology risk assessment tool, when applied at baseline and follow-up, can accurately predict survival in patients with systemic sclerosis-associated pulmonary arterial hypertension, according to data.
Pulmonary arterial hypertension characteristics, mortality vary across US
Among adults with pulmonary arterial hypertension, patient characteristics, mortality and treatment varied across four U.S. census regions, according to results published in Annals of the American Thoracic Society.
Top news of March: FDA PAH approvals, impacts of e-cigarette use
Healio has compiled the most-read news in pulmonology posted in March.
FDA approves sotatercept for pulmonary arterial hypertension
The FDA has approved sotatercept, an activin signaling inhibitor, for treating adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.
FDA approves combination therapy tablet for pulmonary arterial hypertension
The FDA has approved Opsynvi, a once-daily tablet that includes both macitentan and tadalafil, to treat adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.
Benefit of upfront combination therapy not seen in low-risk PAH
Upfront combination therapy for patients with low-risk pulmonary arterial hypertension was not significantly better than monotherapy when assessing time to clinical worsening, according to results published in CHEST.
Pulmonary Hypertension Due to Interstitial Lung Disease (PH-ILD): Optimizing Screening Strategies for Accurate Diagnosis and Timely Intervention
This activity is supported by an educational grant from United Therapeutics, a public benefit company.
Report: Sotatercept improves clinical outcomes in PAH, but unlikely to be cost-effective
When added to background therapy for pulmonary arterial hypertension, sotatercept improves 6-minute walk distance and WHO functional class vs. placebo, according to an evidence report by the Institute for Clinical and Economic Review.
Pulmonary Arterial Hypertension: Stepped, Novel, and Multidisciplinary Approaches to Management
This activity is supported by educational grants from Merck & Co., Inc. and United Therapeutics, a public benefit company.